UEC enters the week deeply in the red — down 21% in a month and 7% in the past week to $9.90 — while short sellers show no sign of retreating and the Street's price targets sit almost double the current price.
The short interest picture is the most pressing story here. Bears hold 12.3% of free float, a level that qualifies as genuinely elevated for a mid-cap uranium producer. That position has grown roughly 2% over the past month, meaning shorts have been adding into the stock's decline rather than covering. Days-to-cover runs close to four days, per the most recent FINRA fortnightly data. Yet the borrow market is not signalling stress: cost to borrow has fallen sharply this week, now at just 0.52% — down 28% in seven days — and availability is a comfortable 174%, well above its 52-week low of 147%. There are roughly 1.7 shares available to borrow for every one already lent out, meaning new short positions remain easy to establish. The lending market is loose, not squeezed.
Options traders are equally relaxed. The put/call ratio of 0.44 is almost exactly in line with its 20-day average, producing a z-score near zero. Critically, the ratio has actually drifted lower from above 0.46 a month ago, suggesting protective demand has not picked up despite the price slide. The 52-week range for PCR runs from 0.15 to 0.79, so the current reading is neither extreme; call volume continues to dominate the options market.
The Street remains constructively positioned, though the gap between analyst targets and the traded price is striking. The consensus mean target is $18.25 — implying roughly 84% upside from $9.90. All recent coverage maintains Buy ratings: HC Wainwright reiterated its Buy at $26.75 in early June, and TD Securities trimmed its target modestly to $21 in March while keeping Buy. Goldman Sachs last moved in September 2025, raising to $17. The bull case centres on Burke Hollow's production start and UEC's domestic supply positioning as the U.S. pushes energy independence. Bears point to Irigaray facility delays, ongoing losses — the PE and EV/EBITDA multiples are deeply negative, reflecting a pre-revenue profile — and the decision to hold back spot uranium sales. Factor scores offer one genuine bright spot: EPS momentum ranks in the 99th percentile on the 30-day reading and 96th on 90 days, while EPS surprise ranks 98th — though these reflect estimate revisions rather than actual profits.
Institutional ownership adds an interesting dimension. T. Rowe Price holds 15.7% of shares, making it the dominant institutional voice; the position increased by roughly 9.7 million shares in the most recent reported period. Mirae Asset, State Street, and Van Eck all added material positions in the quarter ending June 30, providing some offset to the persistent short interest. The ORTEX short score of 65.6 has been stable across the past two weeks, moving in a narrow band between 63.7 and 66.0 — elevated but not accelerating.
The earnings history is worth noting. The most recent print on June 9 produced a one-day move of -25%, the largest recent reaction in either direction, before partially recovering to -7.5% over five days. The prior print in March delivered -5.2% on the day. The next scheduled event is September 24 — the key question heading there is whether UEC can demonstrate operational progress at Burke Hollow and Irigaray in a way that closes the gap between execution reality and the Street's still-bullish targets.
See the live data behind this article on ORTEX.
Open UEC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
